Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Invitrogen™ Complement C9 Monoclonal Antibody (22)
GREENER_CHOICE

Catalog No. ABS0042202
Change view
Click to view available options
Quantity:
400 μL
1 product options available for selection
Product selection table with 1 available options. Use arrow keys to navigate and Enter or Space to select.
Catalog No. Quantity
ABS0042202 400 μL
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 1 options available.
1 options
Catalog No. ABS0042202 Supplier Invitrogen™ Supplier No. ABS0042202
Only null left
Add to Cart
Add to Cart

Mouse Monoclonal Antibody

ABS 004-22-02 is specific for complement factor C9. ABS 004-22-02 has been successfully used in ELISA and Western blot procedures. ABS 004-22-02 recognizes C9 in human serum diluted 1:50 in Tris buffer (20 mM Tris-base, 1 mM MgCl2, 1 mM CaCl2 and 140 mM NaCl) and incubated for 2 hours at 37°C using a human IgM coated (10 μg/mL overnight at 4°C, blocked with PBS 7.2 + 1% BSA for 1 hour) ELISA plate. NOTE: Concentration is lot-dependent and can vary from 0.85-1.15 mg/mL.

C5b-9 membrane attack complexes are assembled from five precursor molecules in the serum. Proteolytic cleavage of C5 by C5 convertase generates C5b which initiates assembly of the C5b-9 complex. The last step of C5b-9 complex formation involves polymerization of C9 which accompanies insertion of the complex into the cell membrane. During formation of C5b-8 and C9 polymerization, neoantigens are generated which are unique to the C5b-9 complex and are not present on any of the individual native complex components. The complement regulatory proteins CD59 and complement S-protein can both prevent C5b-9 insertion into the cell membrane. The formed SC5b-9 complex is unable to attach to cells and is cytolytically inactive. C5b-9 is involved in the progression of chronic proteinuric renal disease by mediating continuous tubulointerstitial damage. Early tubulointerstitial injury in the remnant kidney can be improved when C5b-9 complex forming is abrogated.
TRUSTED_SUSTAINABILITY

Specifications

Antigen Complement C9
Applications ELISA, Immunohistochemistry (Paraffin), Western Blot
Classification Monoclonal
Clone 22
Concentration 1.03 mg/mL
Conjugate Unconjugated
Formulation PBS with 15mM sodium azide; pH 7.4
Gene C9
Gene Accession No. P02748
Gene Alias ARMD15; C9; C9D; complement C9; complement component 9; complement component C9; Complement component C9a; Complement component C9b; complement protein C9; complement protein C9 precursor
Gene Symbols C9
Host Species Mouse
Immunogen Complement component C9.
Purification Method Protein A
Quantity 400 μL
Regulatory Status RUO
Primary or Secondary Primary
Gene ID (Entrez) 735
Target Species Human
Content And Storage 4°C, store in dark
Product Type Antibody
Form Liquid
Isotype IgG1 κ
Show More Show Less
Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.